http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 30 Jul 2026 14:23:10 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Equity+Offerings/60+Degrees+Pharmaceuticals+raises+%241M+in+private+placement/26842610.html <p>60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP, SXTPW) has entered into definitive agreements for a private placement expected to raise approximately $1.0 million in gross proceeds, before placement agent fees and other expenses.</p> <p>The Washington, D.C.-based pharmaceutical company agreed to issue 574,713 shares of common stock, or pre-funded warrants in lieu thereof, along with series A warrants and short-term series B warrants, each to purchase up to 574,713 shares of common stock. The purchase price is $1.74 per share or pre-funded warrant.</p> <p>Both warrant series carry an exercise price of $1.49 per share and are exercisable upon issuance. The series A warrants expire http://www.streetinsider.com/Equity+Offerings/60+Degrees+Pharmaceuticals+raises+%241M+in+private+placement/26842610.html Thu, 30 Jul 2026 14:23:10 -0400 O.58280676 SXTP SXTPW http://www.streetinsider.com/Equity+Offerings/60+Degrees+Pharmaceuticals+raises+%241M+in+private+placement/26842610.html <p>60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP, SXTPW) has entered into definitive agreements for a private placement expected to raise approximately $1.0 million in gross proceeds, before placement agent fees and other expenses.</p> <p>The Washington, D.C.-based pharmaceutical company agreed to issue 574,713 shares of common stock, or pre-funded warrants in lieu thereof, along with series A warrants and short-term series B warrants, each to purchase up to 574,713 shares of common stock. The purchase price is $1.74 per share or pre-funded warrant.</p> <p>Both warrant series carry an exercise price of $1.49 per share and are exercisable upon issuance. The series A warrants expire http://www.streetinsider.com/Equity+Offerings/60+Degrees+Pharmaceuticals+raises+%241M+in+private+placement/26842610.html Thu, 30 Jul 2026 14:23:10 -0400 O.58280676 SXTP SXTPW http://www.streetinsider.com/Equity+Offerings/60+Degrees+Pharmaceuticals+raises+%241M+in+private+placement/26842610.html <p>60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP, SXTPW) has entered into definitive agreements for a private placement expected to raise approximately $1.0 million in gross proceeds, before placement agent fees and other expenses.</p> <p>The Washington, D.C.-based pharmaceutical company agreed to issue 574,713 shares of common stock, or pre-funded warrants in lieu thereof, along with series A warrants and short-term series B warrants, each to purchase up to 574,713 shares of common stock. The purchase price is $1.74 per share or pre-funded warrant.</p> <p>Both warrant series carry an exercise price of $1.49 per share and are exercisable upon issuance. The series A warrants expire http://www.streetinsider.com/Equity+Offerings/60+Degrees+Pharmaceuticals+raises+%241M+in+private+placement/26842610.html Thu, 30 Jul 2026 14:23:10 -0400 O.58280676 SXTP SXTPW http://www.streetinsider.com/Press+Releases/60+Degrees+Pharmaceuticals%2C+Inc.+Announces+Private+Placement+Priced+At-the-Market+Under+Nasdaq+Rules/26842609.html <p align="justify">WASHINGTON, July 30, 2026 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP, SXTPW) (“60 Degrees” or the “Company”), a pharmaceutical company that develops and commercializes new medicines for vector-borne disease, today announced that it has entered into definitive agreements for the issuance and sale of an aggregate of 574,713 shares of its common stock (or pre-funded warrants in lieu thereof), series A warrants to purchase up to 574,713 shares of common stock and short-term series B warrants to purchase up to 574,713 shares of common stock at a purchase price of $1.74 per share (or per http://www.streetinsider.com/Press+Releases/60+Degrees+Pharmaceuticals%2C+Inc.+Announces+Private+Placement+Priced+At-the-Market+Under+Nasdaq+Rules/26842609.html Thu, 30 Jul 2026 14:23:00 -0400 O.58280676 SXTP SXTPW http://www.streetinsider.com/Press+Releases/60+Degrees+Pharmaceuticals%2C+Inc.+Announces+Private+Placement+Priced+At-the-Market+Under+Nasdaq+Rules/26842609.html <p align="justify">WASHINGTON, July 30, 2026 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP, SXTPW) (“60 Degrees” or the “Company”), a pharmaceutical company that develops and commercializes new medicines for vector-borne disease, today announced that it has entered into definitive agreements for the issuance and sale of an aggregate of 574,713 shares of its common stock (or pre-funded warrants in lieu thereof), series A warrants to purchase up to 574,713 shares of common stock and short-term series B warrants to purchase up to 574,713 shares of common stock at a purchase price of $1.74 per share (or per http://www.streetinsider.com/Press+Releases/60+Degrees+Pharmaceuticals%2C+Inc.+Announces+Private+Placement+Priced+At-the-Market+Under+Nasdaq+Rules/26842609.html Thu, 30 Jul 2026 14:23:00 -0400 O.58280676 SXTP SXTPW http://www.streetinsider.com/Press+Releases/60+Degrees+Pharmaceuticals%2C+Inc.+Announces+Private+Placement+Priced+At-the-Market+Under+Nasdaq+Rules/26842609.html <p align="justify">WASHINGTON, July 30, 2026 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP, SXTPW) (“60 Degrees” or the “Company”), a pharmaceutical company that develops and commercializes new medicines for vector-borne disease, today announced that it has entered into definitive agreements for the issuance and sale of an aggregate of 574,713 shares of its common stock (or pre-funded warrants in lieu thereof), series A warrants to purchase up to 574,713 shares of common stock and short-term series B warrants to purchase up to 574,713 shares of common stock at a purchase price of $1.74 per share (or per http://www.streetinsider.com/Press+Releases/60+Degrees+Pharmaceuticals%2C+Inc.+Announces+Private+Placement+Priced+At-the-Market+Under+Nasdaq+Rules/26842609.html Thu, 30 Jul 2026 14:23:00 -0400 O.58280676 SXTP SXTPW http://www.streetinsider.com/Globe+Newswire/60+Degrees+Pharmaceuticals%2C+Inc.+Announces+Private+Placement+Priced+At-the-Market+Under+Nasdaq+Rules/26842609.html <p align="justify">WASHINGTON, July 30, 2026 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP, SXTPW) (“60 Degrees” or the “Company”), a pharmaceutical company that develops and commercializes new medicines for vector-borne disease, today announced that it has entered into definitive agreements for the issuance and sale of an aggregate of 574,713 shares of its common stock (or pre-funded warrants in lieu thereof), series A warrants to purchase up to 574,713 shares of common stock and short-term series B warrants to purchase up to 574,713 shares of common stock at a purchase price of $1.74 per share (or per http://www.streetinsider.com/Globe+Newswire/60+Degrees+Pharmaceuticals%2C+Inc.+Announces+Private+Placement+Priced+At-the-Market+Under+Nasdaq+Rules/26842609.html Thu, 30 Jul 2026 14:23:00 -0400 O.58280676 SXTP SXTPW http://www.streetinsider.com/Globe+Newswire/60+Degrees+Pharmaceuticals%2C+Inc.+Announces+Private+Placement+Priced+At-the-Market+Under+Nasdaq+Rules/26842609.html <p align="justify">WASHINGTON, July 30, 2026 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP, SXTPW) (“60 Degrees” or the “Company”), a pharmaceutical company that develops and commercializes new medicines for vector-borne disease, today announced that it has entered into definitive agreements for the issuance and sale of an aggregate of 574,713 shares of its common stock (or pre-funded warrants in lieu thereof), series A warrants to purchase up to 574,713 shares of common stock and short-term series B warrants to purchase up to 574,713 shares of common stock at a purchase price of $1.74 per share (or per http://www.streetinsider.com/Globe+Newswire/60+Degrees+Pharmaceuticals%2C+Inc.+Announces+Private+Placement+Priced+At-the-Market+Under+Nasdaq+Rules/26842609.html Thu, 30 Jul 2026 14:23:00 -0400 O.58280676 SXTP SXTPW http://www.streetinsider.com/Globe+Newswire/60+Degrees+Pharmaceuticals%2C+Inc.+Announces+Private+Placement+Priced+At-the-Market+Under+Nasdaq+Rules/26842609.html <p align="justify">WASHINGTON, July 30, 2026 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP, SXTPW) (“60 Degrees” or the “Company”), a pharmaceutical company that develops and commercializes new medicines for vector-borne disease, today announced that it has entered into definitive agreements for the issuance and sale of an aggregate of 574,713 shares of its common stock (or pre-funded warrants in lieu thereof), series A warrants to purchase up to 574,713 shares of common stock and short-term series B warrants to purchase up to 574,713 shares of common stock at a purchase price of $1.74 per share (or per http://www.streetinsider.com/Globe+Newswire/60+Degrees+Pharmaceuticals%2C+Inc.+Announces+Private+Placement+Priced+At-the-Market+Under+Nasdaq+Rules/26842609.html Thu, 30 Jul 2026 14:23:00 -0400 O.58280676 SXTP SXTPW http://www.streetinsider.com/Press+Releases/60+Degrees+Pharmaceuticals+Announces+Minimum+Enrollment+Achieved+in+Hospitalized+Babesiosis+Study%3B+Interim+Data+Readout+Planned+by+October+6%2C+2026/26834756.html <ul type="disc"><li>Company plans to request an FDA meeting following the interim readout to discuss the regulatory pathway for a New Drug Application (NDA) for tafenoquine in babesiosis<br/><br/></li></ul> <p>WASHINGTON, July 29, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=e3xqchGoZRA65arYOoma5FsDWHd4kBurHMdAF9N64kEkzOg23dpanNnD67wDoaJi4ItNd3eTHY205oqu6mjLdx7oD-eBeTcvCPUAx-GCSJQegZ1ZTtwseH5X-skunQ19DuEc_EoCpTAIJOGBrHBOYA==" rel="nofollow" target="_blank">60 Degrees Pharmaceuticals, Inc.</a> (NASDAQ: SXTP; SXTPW) (“60 Degrees” or the “Company”), a pharmaceutical company that develops and commercializes new medicines for vector-borne disease, today announced it has enrolled the minimum 24 patients needed to trigger an interim analysis in its clinical study of patients hospitalized with severe babesiosis (<a target="_blank" href="https://www.globenewswire.com/Tracker?data=KRAXs0j4X6H0suvFY5fB-uZOXsyOCKtQHUSTNnIRJTGL_4JWngwUc_tYf15dny2pKB3Vwf7j9l3Tl7fI1eqlD931PimKIUfXOu9e6YrzVqYGgPim_pu9JHVGc1QoFAlewozbmuDgsID_9wMyjfd2Cg==" rel="nofollow" target="_blank">NCT06207370</a>). The outcome of the interim analysis http://www.streetinsider.com/Press+Releases/60+Degrees+Pharmaceuticals+Announces+Minimum+Enrollment+Achieved+in+Hospitalized+Babesiosis+Study%3B+Interim+Data+Readout+Planned+by+October+6%2C+2026/26834756.html Wed, 29 Jul 2026 16:03:00 -0400 A.00641573 A.06822034 A.13379936 A.23195496 A.32073079 O.00168656 O.02027210 O.02114916 O.19918614 O.20026344 O.58280676 SXTP SXTPW http://www.streetinsider.com/Press+Releases/60+Degrees+Pharmaceuticals+Announces+Minimum+Enrollment+Achieved+in+Hospitalized+Babesiosis+Study%3B+Interim+Data+Readout+Planned+by+October+6%2C+2026/26834756.html <ul type="disc"><li>Company plans to request an FDA meeting following the interim readout to discuss the regulatory pathway for a New Drug Application (NDA) for tafenoquine in babesiosis<br/><br/></li></ul> <p>WASHINGTON, July 29, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=e3xqchGoZRA65arYOoma5FsDWHd4kBurHMdAF9N64kEkzOg23dpanNnD67wDoaJi4ItNd3eTHY205oqu6mjLdx7oD-eBeTcvCPUAx-GCSJQegZ1ZTtwseH5X-skunQ19DuEc_EoCpTAIJOGBrHBOYA==" rel="nofollow" target="_blank">60 Degrees Pharmaceuticals, Inc.</a> (NASDAQ: SXTP; SXTPW) (“60 Degrees” or the “Company”), a pharmaceutical company that develops and commercializes new medicines for vector-borne disease, today announced it has enrolled the minimum 24 patients needed to trigger an interim analysis in its clinical study of patients hospitalized with severe babesiosis (<a target="_blank" href="https://www.globenewswire.com/Tracker?data=KRAXs0j4X6H0suvFY5fB-uZOXsyOCKtQHUSTNnIRJTGL_4JWngwUc_tYf15dny2pKB3Vwf7j9l3Tl7fI1eqlD931PimKIUfXOu9e6YrzVqYGgPim_pu9JHVGc1QoFAlewozbmuDgsID_9wMyjfd2Cg==" rel="nofollow" target="_blank">NCT06207370</a>). The outcome of the interim analysis http://www.streetinsider.com/Press+Releases/60+Degrees+Pharmaceuticals+Announces+Minimum+Enrollment+Achieved+in+Hospitalized+Babesiosis+Study%3B+Interim+Data+Readout+Planned+by+October+6%2C+2026/26834756.html Wed, 29 Jul 2026 16:03:00 -0400 A.00641573 A.06822034 A.13379936 A.23195496 A.32073079 O.00168656 O.02027210 O.02114916 O.19918614 O.20026344 O.58280676 SXTP SXTPW http://www.streetinsider.com/Press+Releases/60+Degrees+Pharmaceuticals+Announces+Minimum+Enrollment+Achieved+in+Hospitalized+Babesiosis+Study%3B+Interim+Data+Readout+Planned+by+October+6%2C+2026/26834756.html <ul type="disc"><li>Company plans to request an FDA meeting following the interim readout to discuss the regulatory pathway for a New Drug Application (NDA) for tafenoquine in babesiosis<br/><br/></li></ul> <p>WASHINGTON, July 29, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=e3xqchGoZRA65arYOoma5FsDWHd4kBurHMdAF9N64kEkzOg23dpanNnD67wDoaJi4ItNd3eTHY205oqu6mjLdx7oD-eBeTcvCPUAx-GCSJQegZ1ZTtwseH5X-skunQ19DuEc_EoCpTAIJOGBrHBOYA==" rel="nofollow" target="_blank">60 Degrees Pharmaceuticals, Inc.</a> (NASDAQ: SXTP; SXTPW) (“60 Degrees” or the “Company”), a pharmaceutical company that develops and commercializes new medicines for vector-borne disease, today announced it has enrolled the minimum 24 patients needed to trigger an interim analysis in its clinical study of patients hospitalized with severe babesiosis (<a target="_blank" href="https://www.globenewswire.com/Tracker?data=KRAXs0j4X6H0suvFY5fB-uZOXsyOCKtQHUSTNnIRJTGL_4JWngwUc_tYf15dny2pKB3Vwf7j9l3Tl7fI1eqlD931PimKIUfXOu9e6YrzVqYGgPim_pu9JHVGc1QoFAlewozbmuDgsID_9wMyjfd2Cg==" rel="nofollow" target="_blank">NCT06207370</a>). The outcome of the interim analysis http://www.streetinsider.com/Press+Releases/60+Degrees+Pharmaceuticals+Announces+Minimum+Enrollment+Achieved+in+Hospitalized+Babesiosis+Study%3B+Interim+Data+Readout+Planned+by+October+6%2C+2026/26834756.html Wed, 29 Jul 2026 16:03:00 -0400 A.00641573 A.06822034 A.13379936 A.23195496 A.32073079 O.00168656 O.02027210 O.02114916 O.19918614 O.20026344 O.58280676 SXTP SXTPW http://www.streetinsider.com/Press+Releases/60+Degrees+Pharmaceuticals+Announces+Minimum+Enrollment+Achieved+in+Hospitalized+Babesiosis+Study%3B+Interim+Data+Readout+Planned+by+October+6%2C+2026/26834756.html <ul type="disc"><li>Company plans to request an FDA meeting following the interim readout to discuss the regulatory pathway for a New Drug Application (NDA) for tafenoquine in babesiosis<br/><br/></li></ul> <p>WASHINGTON, July 29, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=e3xqchGoZRA65arYOoma5FsDWHd4kBurHMdAF9N64kEkzOg23dpanNnD67wDoaJi4ItNd3eTHY205oqu6mjLdx7oD-eBeTcvCPUAx-GCSJQegZ1ZTtwseH5X-skunQ19DuEc_EoCpTAIJOGBrHBOYA==" rel="nofollow" target="_blank">60 Degrees Pharmaceuticals, Inc.</a> (NASDAQ: SXTP; SXTPW) (“60 Degrees” or the “Company”), a pharmaceutical company that develops and commercializes new medicines for vector-borne disease, today announced it has enrolled the minimum 24 patients needed to trigger an interim analysis in its clinical study of patients hospitalized with severe babesiosis (<a target="_blank" href="https://www.globenewswire.com/Tracker?data=KRAXs0j4X6H0suvFY5fB-uZOXsyOCKtQHUSTNnIRJTGL_4JWngwUc_tYf15dny2pKB3Vwf7j9l3Tl7fI1eqlD931PimKIUfXOu9e6YrzVqYGgPim_pu9JHVGc1QoFAlewozbmuDgsID_9wMyjfd2Cg==" rel="nofollow" target="_blank">NCT06207370</a>). The outcome of the interim analysis http://www.streetinsider.com/Press+Releases/60+Degrees+Pharmaceuticals+Announces+Minimum+Enrollment+Achieved+in+Hospitalized+Babesiosis+Study%3B+Interim+Data+Readout+Planned+by+October+6%2C+2026/26834756.html Wed, 29 Jul 2026 16:03:00 -0400 A.00641573 A.06822034 A.13379936 A.23195496 A.32073079 O.00168656 O.02027210 O.02114916 O.19918614 O.20026344 O.58280676 SXTP SXTPW http://www.streetinsider.com/Press+Releases/60+Degrees+Pharmaceuticals+Announces+Minimum+Enrollment+Achieved+in+Hospitalized+Babesiosis+Study%3B+Interim+Data+Readout+Planned+by+October+6%2C+2026/26834756.html <ul type="disc"><li>Company plans to request an FDA meeting following the interim readout to discuss the regulatory pathway for a New Drug Application (NDA) for tafenoquine in babesiosis<br/><br/></li></ul> <p>WASHINGTON, July 29, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=e3xqchGoZRA65arYOoma5FsDWHd4kBurHMdAF9N64kEkzOg23dpanNnD67wDoaJi4ItNd3eTHY205oqu6mjLdx7oD-eBeTcvCPUAx-GCSJQegZ1ZTtwseH5X-skunQ19DuEc_EoCpTAIJOGBrHBOYA==" rel="nofollow" target="_blank">60 Degrees Pharmaceuticals, Inc.</a> (NASDAQ: SXTP; SXTPW) (“60 Degrees” or the “Company”), a pharmaceutical company that develops and commercializes new medicines for vector-borne disease, today announced it has enrolled the minimum 24 patients needed to trigger an interim analysis in its clinical study of patients hospitalized with severe babesiosis (<a target="_blank" href="https://www.globenewswire.com/Tracker?data=KRAXs0j4X6H0suvFY5fB-uZOXsyOCKtQHUSTNnIRJTGL_4JWngwUc_tYf15dny2pKB3Vwf7j9l3Tl7fI1eqlD931PimKIUfXOu9e6YrzVqYGgPim_pu9JHVGc1QoFAlewozbmuDgsID_9wMyjfd2Cg==" rel="nofollow" target="_blank">NCT06207370</a>). The outcome of the interim analysis http://www.streetinsider.com/Press+Releases/60+Degrees+Pharmaceuticals+Announces+Minimum+Enrollment+Achieved+in+Hospitalized+Babesiosis+Study%3B+Interim+Data+Readout+Planned+by+October+6%2C+2026/26834756.html Wed, 29 Jul 2026 16:03:00 -0400 A.00641573 A.06822034 A.13379936 A.23195496 A.32073079 O.00168656 O.02027210 O.02114916 O.19918614 O.20026344 O.58280676 SXTP SXTPW http://www.streetinsider.com/Press+Releases/60+Degrees+Pharmaceuticals+Announces+Minimum+Enrollment+Achieved+in+Hospitalized+Babesiosis+Study%3B+Interim+Data+Readout+Planned+by+October+6%2C+2026/26834756.html <ul type="disc"><li>Company plans to request an FDA meeting following the interim readout to discuss the regulatory pathway for a New Drug Application (NDA) for tafenoquine in babesiosis<br/><br/></li></ul> <p>WASHINGTON, July 29, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=e3xqchGoZRA65arYOoma5FsDWHd4kBurHMdAF9N64kEkzOg23dpanNnD67wDoaJi4ItNd3eTHY205oqu6mjLdx7oD-eBeTcvCPUAx-GCSJQegZ1ZTtwseH5X-skunQ19DuEc_EoCpTAIJOGBrHBOYA==" rel="nofollow" target="_blank">60 Degrees Pharmaceuticals, Inc.</a> (NASDAQ: SXTP; SXTPW) (“60 Degrees” or the “Company”), a pharmaceutical company that develops and commercializes new medicines for vector-borne disease, today announced it has enrolled the minimum 24 patients needed to trigger an interim analysis in its clinical study of patients hospitalized with severe babesiosis (<a target="_blank" href="https://www.globenewswire.com/Tracker?data=KRAXs0j4X6H0suvFY5fB-uZOXsyOCKtQHUSTNnIRJTGL_4JWngwUc_tYf15dny2pKB3Vwf7j9l3Tl7fI1eqlD931PimKIUfXOu9e6YrzVqYGgPim_pu9JHVGc1QoFAlewozbmuDgsID_9wMyjfd2Cg==" rel="nofollow" target="_blank">NCT06207370</a>). The outcome of the interim analysis http://www.streetinsider.com/Press+Releases/60+Degrees+Pharmaceuticals+Announces+Minimum+Enrollment+Achieved+in+Hospitalized+Babesiosis+Study%3B+Interim+Data+Readout+Planned+by+October+6%2C+2026/26834756.html Wed, 29 Jul 2026 16:03:00 -0400 A.00641573 A.06822034 A.13379936 A.23195496 A.32073079 O.00168656 O.02027210 O.02114916 O.19918614 O.20026344 O.58280676 SXTP SXTPW http://www.streetinsider.com/Press+Releases/60+Degrees+Pharmaceuticals+Announces+Minimum+Enrollment+Achieved+in+Hospitalized+Babesiosis+Study%3B+Interim+Data+Readout+Planned+by+October+6%2C+2026/26834756.html <ul type="disc"><li>Company plans to request an FDA meeting following the interim readout to discuss the regulatory pathway for a New Drug Application (NDA) for tafenoquine in babesiosis<br/><br/></li></ul> <p>WASHINGTON, July 29, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=e3xqchGoZRA65arYOoma5FsDWHd4kBurHMdAF9N64kEkzOg23dpanNnD67wDoaJi4ItNd3eTHY205oqu6mjLdx7oD-eBeTcvCPUAx-GCSJQegZ1ZTtwseH5X-skunQ19DuEc_EoCpTAIJOGBrHBOYA==" rel="nofollow" target="_blank">60 Degrees Pharmaceuticals, Inc.</a> (NASDAQ: SXTP; SXTPW) (“60 Degrees” or the “Company”), a pharmaceutical company that develops and commercializes new medicines for vector-borne disease, today announced it has enrolled the minimum 24 patients needed to trigger an interim analysis in its clinical study of patients hospitalized with severe babesiosis (<a target="_blank" href="https://www.globenewswire.com/Tracker?data=KRAXs0j4X6H0suvFY5fB-uZOXsyOCKtQHUSTNnIRJTGL_4JWngwUc_tYf15dny2pKB3Vwf7j9l3Tl7fI1eqlD931PimKIUfXOu9e6YrzVqYGgPim_pu9JHVGc1QoFAlewozbmuDgsID_9wMyjfd2Cg==" rel="nofollow" target="_blank">NCT06207370</a>). The outcome of the interim analysis http://www.streetinsider.com/Press+Releases/60+Degrees+Pharmaceuticals+Announces+Minimum+Enrollment+Achieved+in+Hospitalized+Babesiosis+Study%3B+Interim+Data+Readout+Planned+by+October+6%2C+2026/26834756.html Wed, 29 Jul 2026 16:03:00 -0400 A.00641573 A.06822034 A.13379936 A.23195496 A.32073079 O.00168656 O.02027210 O.02114916 O.19918614 O.20026344 O.58280676 SXTP SXTPW http://www.streetinsider.com/Press+Releases/60+Degrees+Pharmaceuticals+Announces+Minimum+Enrollment+Achieved+in+Hospitalized+Babesiosis+Study%3B+Interim+Data+Readout+Planned+by+October+6%2C+2026/26834756.html <ul type="disc"><li>Company plans to request an FDA meeting following the interim readout to discuss the regulatory pathway for a New Drug Application (NDA) for tafenoquine in babesiosis<br/><br/></li></ul> <p>WASHINGTON, July 29, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=e3xqchGoZRA65arYOoma5FsDWHd4kBurHMdAF9N64kEkzOg23dpanNnD67wDoaJi4ItNd3eTHY205oqu6mjLdx7oD-eBeTcvCPUAx-GCSJQegZ1ZTtwseH5X-skunQ19DuEc_EoCpTAIJOGBrHBOYA==" rel="nofollow" target="_blank">60 Degrees Pharmaceuticals, Inc.</a> (NASDAQ: SXTP; SXTPW) (“60 Degrees” or the “Company”), a pharmaceutical company that develops and commercializes new medicines for vector-borne disease, today announced it has enrolled the minimum 24 patients needed to trigger an interim analysis in its clinical study of patients hospitalized with severe babesiosis (<a target="_blank" href="https://www.globenewswire.com/Tracker?data=KRAXs0j4X6H0suvFY5fB-uZOXsyOCKtQHUSTNnIRJTGL_4JWngwUc_tYf15dny2pKB3Vwf7j9l3Tl7fI1eqlD931PimKIUfXOu9e6YrzVqYGgPim_pu9JHVGc1QoFAlewozbmuDgsID_9wMyjfd2Cg==" rel="nofollow" target="_blank">NCT06207370</a>). The outcome of the interim analysis http://www.streetinsider.com/Press+Releases/60+Degrees+Pharmaceuticals+Announces+Minimum+Enrollment+Achieved+in+Hospitalized+Babesiosis+Study%3B+Interim+Data+Readout+Planned+by+October+6%2C+2026/26834756.html Wed, 29 Jul 2026 16:03:00 -0400 A.00641573 A.06822034 A.13379936 A.23195496 A.32073079 O.00168656 O.02027210 O.02114916 O.19918614 O.20026344 O.58280676 SXTP SXTPW http://www.streetinsider.com/Press+Releases/60+Degrees+Pharmaceuticals+Announces+Minimum+Enrollment+Achieved+in+Hospitalized+Babesiosis+Study%3B+Interim+Data+Readout+Planned+by+October+6%2C+2026/26834756.html <ul type="disc"><li>Company plans to request an FDA meeting following the interim readout to discuss the regulatory pathway for a New Drug Application (NDA) for tafenoquine in babesiosis<br/><br/></li></ul> <p>WASHINGTON, July 29, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=e3xqchGoZRA65arYOoma5FsDWHd4kBurHMdAF9N64kEkzOg23dpanNnD67wDoaJi4ItNd3eTHY205oqu6mjLdx7oD-eBeTcvCPUAx-GCSJQegZ1ZTtwseH5X-skunQ19DuEc_EoCpTAIJOGBrHBOYA==" rel="nofollow" target="_blank">60 Degrees Pharmaceuticals, Inc.</a> (NASDAQ: SXTP; SXTPW) (“60 Degrees” or the “Company”), a pharmaceutical company that develops and commercializes new medicines for vector-borne disease, today announced it has enrolled the minimum 24 patients needed to trigger an interim analysis in its clinical study of patients hospitalized with severe babesiosis (<a target="_blank" href="https://www.globenewswire.com/Tracker?data=KRAXs0j4X6H0suvFY5fB-uZOXsyOCKtQHUSTNnIRJTGL_4JWngwUc_tYf15dny2pKB3Vwf7j9l3Tl7fI1eqlD931PimKIUfXOu9e6YrzVqYGgPim_pu9JHVGc1QoFAlewozbmuDgsID_9wMyjfd2Cg==" rel="nofollow" target="_blank">NCT06207370</a>). The outcome of the interim analysis http://www.streetinsider.com/Press+Releases/60+Degrees+Pharmaceuticals+Announces+Minimum+Enrollment+Achieved+in+Hospitalized+Babesiosis+Study%3B+Interim+Data+Readout+Planned+by+October+6%2C+2026/26834756.html Wed, 29 Jul 2026 16:03:00 -0400 A.00641573 A.06822034 A.13379936 A.23195496 A.32073079 O.00168656 O.02027210 O.02114916 O.19918614 O.20026344 O.58280676 SXTP SXTPW http://www.streetinsider.com/Press+Releases/60+Degrees+Pharmaceuticals+Announces+Minimum+Enrollment+Achieved+in+Hospitalized+Babesiosis+Study%3B+Interim+Data+Readout+Planned+by+October+6%2C+2026/26834756.html <ul type="disc"><li>Company plans to request an FDA meeting following the interim readout to discuss the regulatory pathway for a New Drug Application (NDA) for tafenoquine in babesiosis<br/><br/></li></ul> <p>WASHINGTON, July 29, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=e3xqchGoZRA65arYOoma5FsDWHd4kBurHMdAF9N64kEkzOg23dpanNnD67wDoaJi4ItNd3eTHY205oqu6mjLdx7oD-eBeTcvCPUAx-GCSJQegZ1ZTtwseH5X-skunQ19DuEc_EoCpTAIJOGBrHBOYA==" rel="nofollow" target="_blank">60 Degrees Pharmaceuticals, Inc.</a> (NASDAQ: SXTP; SXTPW) (“60 Degrees” or the “Company”), a pharmaceutical company that develops and commercializes new medicines for vector-borne disease, today announced it has enrolled the minimum 24 patients needed to trigger an interim analysis in its clinical study of patients hospitalized with severe babesiosis (<a target="_blank" href="https://www.globenewswire.com/Tracker?data=KRAXs0j4X6H0suvFY5fB-uZOXsyOCKtQHUSTNnIRJTGL_4JWngwUc_tYf15dny2pKB3Vwf7j9l3Tl7fI1eqlD931PimKIUfXOu9e6YrzVqYGgPim_pu9JHVGc1QoFAlewozbmuDgsID_9wMyjfd2Cg==" rel="nofollow" target="_blank">NCT06207370</a>). The outcome of the interim analysis http://www.streetinsider.com/Press+Releases/60+Degrees+Pharmaceuticals+Announces+Minimum+Enrollment+Achieved+in+Hospitalized+Babesiosis+Study%3B+Interim+Data+Readout+Planned+by+October+6%2C+2026/26834756.html Wed, 29 Jul 2026 16:03:00 -0400 A.00641573 A.06822034 A.13379936 A.23195496 A.32073079 O.00168656 O.02027210 O.02114916 O.19918614 O.20026344 O.58280676 SXTP SXTPW http://www.streetinsider.com/Press+Releases/60+Degrees+Pharmaceuticals+Announces+Minimum+Enrollment+Achieved+in+Hospitalized+Babesiosis+Study%3B+Interim+Data+Readout+Planned+by+October+6%2C+2026/26834756.html <ul type="disc"><li>Company plans to request an FDA meeting following the interim readout to discuss the regulatory pathway for a New Drug Application (NDA) for tafenoquine in babesiosis<br/><br/></li></ul> <p>WASHINGTON, July 29, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=e3xqchGoZRA65arYOoma5FsDWHd4kBurHMdAF9N64kEkzOg23dpanNnD67wDoaJi4ItNd3eTHY205oqu6mjLdx7oD-eBeTcvCPUAx-GCSJQegZ1ZTtwseH5X-skunQ19DuEc_EoCpTAIJOGBrHBOYA==" rel="nofollow" target="_blank">60 Degrees Pharmaceuticals, Inc.</a> (NASDAQ: SXTP; SXTPW) (“60 Degrees” or the “Company”), a pharmaceutical company that develops and commercializes new medicines for vector-borne disease, today announced it has enrolled the minimum 24 patients needed to trigger an interim analysis in its clinical study of patients hospitalized with severe babesiosis (<a target="_blank" href="https://www.globenewswire.com/Tracker?data=KRAXs0j4X6H0suvFY5fB-uZOXsyOCKtQHUSTNnIRJTGL_4JWngwUc_tYf15dny2pKB3Vwf7j9l3Tl7fI1eqlD931PimKIUfXOu9e6YrzVqYGgPim_pu9JHVGc1QoFAlewozbmuDgsID_9wMyjfd2Cg==" rel="nofollow" target="_blank">NCT06207370</a>). The outcome of the interim analysis http://www.streetinsider.com/Press+Releases/60+Degrees+Pharmaceuticals+Announces+Minimum+Enrollment+Achieved+in+Hospitalized+Babesiosis+Study%3B+Interim+Data+Readout+Planned+by+October+6%2C+2026/26834756.html Wed, 29 Jul 2026 16:03:00 -0400 A.00641573 A.06822034 A.13379936 A.23195496 A.32073079 O.00168656 O.02027210 O.02114916 O.19918614 O.20026344 O.58280676 SXTP SXTPW http://www.streetinsider.com/Press+Releases/60+Degrees+Pharmaceuticals+Announces+Minimum+Enrollment+Achieved+in+Hospitalized+Babesiosis+Study%3B+Interim+Data+Readout+Planned+by+October+6%2C+2026/26834756.html <ul type="disc"><li>Company plans to request an FDA meeting following the interim readout to discuss the regulatory pathway for a New Drug Application (NDA) for tafenoquine in babesiosis<br/><br/></li></ul> <p>WASHINGTON, July 29, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=e3xqchGoZRA65arYOoma5FsDWHd4kBurHMdAF9N64kEkzOg23dpanNnD67wDoaJi4ItNd3eTHY205oqu6mjLdx7oD-eBeTcvCPUAx-GCSJQegZ1ZTtwseH5X-skunQ19DuEc_EoCpTAIJOGBrHBOYA==" rel="nofollow" target="_blank">60 Degrees Pharmaceuticals, Inc.</a> (NASDAQ: SXTP; SXTPW) (“60 Degrees” or the “Company”), a pharmaceutical company that develops and commercializes new medicines for vector-borne disease, today announced it has enrolled the minimum 24 patients needed to trigger an interim analysis in its clinical study of patients hospitalized with severe babesiosis (<a target="_blank" href="https://www.globenewswire.com/Tracker?data=KRAXs0j4X6H0suvFY5fB-uZOXsyOCKtQHUSTNnIRJTGL_4JWngwUc_tYf15dny2pKB3Vwf7j9l3Tl7fI1eqlD931PimKIUfXOu9e6YrzVqYGgPim_pu9JHVGc1QoFAlewozbmuDgsID_9wMyjfd2Cg==" rel="nofollow" target="_blank">NCT06207370</a>). The outcome of the interim analysis http://www.streetinsider.com/Press+Releases/60+Degrees+Pharmaceuticals+Announces+Minimum+Enrollment+Achieved+in+Hospitalized+Babesiosis+Study%3B+Interim+Data+Readout+Planned+by+October+6%2C+2026/26834756.html Wed, 29 Jul 2026 16:03:00 -0400 A.00641573 A.06822034 A.13379936 A.23195496 A.32073079 O.00168656 O.02027210 O.02114916 O.19918614 O.20026344 O.58280676 SXTP SXTPW http://www.streetinsider.com/Press+Releases/60+Degrees+Pharmaceuticals+Announces+Minimum+Enrollment+Achieved+in+Hospitalized+Babesiosis+Study%3B+Interim+Data+Readout+Planned+by+October+6%2C+2026/26834756.html <ul type="disc"><li>Company plans to request an FDA meeting following the interim readout to discuss the regulatory pathway for a New Drug Application (NDA) for tafenoquine in babesiosis<br/><br/></li></ul> <p>WASHINGTON, July 29, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=e3xqchGoZRA65arYOoma5FsDWHd4kBurHMdAF9N64kEkzOg23dpanNnD67wDoaJi4ItNd3eTHY205oqu6mjLdx7oD-eBeTcvCPUAx-GCSJQegZ1ZTtwseH5X-skunQ19DuEc_EoCpTAIJOGBrHBOYA==" rel="nofollow" target="_blank">60 Degrees Pharmaceuticals, Inc.</a> (NASDAQ: SXTP; SXTPW) (“60 Degrees” or the “Company”), a pharmaceutical company that develops and commercializes new medicines for vector-borne disease, today announced it has enrolled the minimum 24 patients needed to trigger an interim analysis in its clinical study of patients hospitalized with severe babesiosis (<a target="_blank" href="https://www.globenewswire.com/Tracker?data=KRAXs0j4X6H0suvFY5fB-uZOXsyOCKtQHUSTNnIRJTGL_4JWngwUc_tYf15dny2pKB3Vwf7j9l3Tl7fI1eqlD931PimKIUfXOu9e6YrzVqYGgPim_pu9JHVGc1QoFAlewozbmuDgsID_9wMyjfd2Cg==" rel="nofollow" target="_blank">NCT06207370</a>). The outcome of the interim analysis http://www.streetinsider.com/Press+Releases/60+Degrees+Pharmaceuticals+Announces+Minimum+Enrollment+Achieved+in+Hospitalized+Babesiosis+Study%3B+Interim+Data+Readout+Planned+by+October+6%2C+2026/26834756.html Wed, 29 Jul 2026 16:03:00 -0400 A.00641573 A.06822034 A.13379936 A.23195496 A.32073079 O.00168656 O.02027210 O.02114916 O.19918614 O.20026344 O.58280676 SXTP SXTPW http://www.streetinsider.com/Globe+Newswire/60+Degrees+Pharmaceuticals+Announces+Minimum+Enrollment+Achieved+in+Hospitalized+Babesiosis+Study%3B+Interim+Data+Readout+Planned+by+October+6%2C+2026/26834756.html <ul type="disc"><li>Company plans to request an FDA meeting following the interim readout to discuss the regulatory pathway for a New Drug Application (NDA) for tafenoquine in babesiosis<br/><br/></li></ul> <p>WASHINGTON, July 29, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=e3xqchGoZRA65arYOoma5FsDWHd4kBurHMdAF9N64kEkzOg23dpanNnD67wDoaJi4ItNd3eTHY205oqu6mjLdx7oD-eBeTcvCPUAx-GCSJQegZ1ZTtwseH5X-skunQ19DuEc_EoCpTAIJOGBrHBOYA==" rel="nofollow" target="_blank">60 Degrees Pharmaceuticals, Inc.</a> (NASDAQ: SXTP; SXTPW) (“60 Degrees” or the “Company”), a pharmaceutical company that develops and commercializes new medicines for vector-borne disease, today announced it has enrolled the minimum 24 patients needed to trigger an interim analysis in its clinical study of patients hospitalized with severe babesiosis (<a target="_blank" href="https://www.globenewswire.com/Tracker?data=KRAXs0j4X6H0suvFY5fB-uZOXsyOCKtQHUSTNnIRJTGL_4JWngwUc_tYf15dny2pKB3Vwf7j9l3Tl7fI1eqlD931PimKIUfXOu9e6YrzVqYGgPim_pu9JHVGc1QoFAlewozbmuDgsID_9wMyjfd2Cg==" rel="nofollow" target="_blank">NCT06207370</a>). The outcome of the interim analysis http://www.streetinsider.com/Globe+Newswire/60+Degrees+Pharmaceuticals+Announces+Minimum+Enrollment+Achieved+in+Hospitalized+Babesiosis+Study%3B+Interim+Data+Readout+Planned+by+October+6%2C+2026/26834756.html Wed, 29 Jul 2026 16:03:00 -0400 A.00641573 A.06822034 A.13379936 A.23195496 A.32073079 O.00168656 O.02027210 O.02114916 O.19918614 O.20026344 O.58280676 SXTP SXTPW http://www.streetinsider.com/Globe+Newswire/60+Degrees+Pharmaceuticals+Announces+Minimum+Enrollment+Achieved+in+Hospitalized+Babesiosis+Study%3B+Interim+Data+Readout+Planned+by+October+6%2C+2026/26834756.html <ul type="disc"><li>Company plans to request an FDA meeting following the interim readout to discuss the regulatory pathway for a New Drug Application (NDA) for tafenoquine in babesiosis<br/><br/></li></ul> <p>WASHINGTON, July 29, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=e3xqchGoZRA65arYOoma5FsDWHd4kBurHMdAF9N64kEkzOg23dpanNnD67wDoaJi4ItNd3eTHY205oqu6mjLdx7oD-eBeTcvCPUAx-GCSJQegZ1ZTtwseH5X-skunQ19DuEc_EoCpTAIJOGBrHBOYA==" rel="nofollow" target="_blank">60 Degrees Pharmaceuticals, Inc.</a> (NASDAQ: SXTP; SXTPW) (“60 Degrees” or the “Company”), a pharmaceutical company that develops and commercializes new medicines for vector-borne disease, today announced it has enrolled the minimum 24 patients needed to trigger an interim analysis in its clinical study of patients hospitalized with severe babesiosis (<a target="_blank" href="https://www.globenewswire.com/Tracker?data=KRAXs0j4X6H0suvFY5fB-uZOXsyOCKtQHUSTNnIRJTGL_4JWngwUc_tYf15dny2pKB3Vwf7j9l3Tl7fI1eqlD931PimKIUfXOu9e6YrzVqYGgPim_pu9JHVGc1QoFAlewozbmuDgsID_9wMyjfd2Cg==" rel="nofollow" target="_blank">NCT06207370</a>). The outcome of the interim analysis http://www.streetinsider.com/Globe+Newswire/60+Degrees+Pharmaceuticals+Announces+Minimum+Enrollment+Achieved+in+Hospitalized+Babesiosis+Study%3B+Interim+Data+Readout+Planned+by+October+6%2C+2026/26834756.html Wed, 29 Jul 2026 16:03:00 -0400 A.00641573 A.06822034 A.13379936 A.23195496 A.32073079 O.00168656 O.02027210 O.02114916 O.19918614 O.20026344 O.58280676 SXTP SXTPW http://www.streetinsider.com/Globe+Newswire/60+Degrees+Pharmaceuticals+Announces+Minimum+Enrollment+Achieved+in+Hospitalized+Babesiosis+Study%3B+Interim+Data+Readout+Planned+by+October+6%2C+2026/26834756.html <ul type="disc"><li>Company plans to request an FDA meeting following the interim readout to discuss the regulatory pathway for a New Drug Application (NDA) for tafenoquine in babesiosis<br/><br/></li></ul> <p>WASHINGTON, July 29, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=e3xqchGoZRA65arYOoma5FsDWHd4kBurHMdAF9N64kEkzOg23dpanNnD67wDoaJi4ItNd3eTHY205oqu6mjLdx7oD-eBeTcvCPUAx-GCSJQegZ1ZTtwseH5X-skunQ19DuEc_EoCpTAIJOGBrHBOYA==" rel="nofollow" target="_blank">60 Degrees Pharmaceuticals, Inc.</a> (NASDAQ: SXTP; SXTPW) (“60 Degrees” or the “Company”), a pharmaceutical company that develops and commercializes new medicines for vector-borne disease, today announced it has enrolled the minimum 24 patients needed to trigger an interim analysis in its clinical study of patients hospitalized with severe babesiosis (<a target="_blank" href="https://www.globenewswire.com/Tracker?data=KRAXs0j4X6H0suvFY5fB-uZOXsyOCKtQHUSTNnIRJTGL_4JWngwUc_tYf15dny2pKB3Vwf7j9l3Tl7fI1eqlD931PimKIUfXOu9e6YrzVqYGgPim_pu9JHVGc1QoFAlewozbmuDgsID_9wMyjfd2Cg==" rel="nofollow" target="_blank">NCT06207370</a>). The outcome of the interim analysis http://www.streetinsider.com/Globe+Newswire/60+Degrees+Pharmaceuticals+Announces+Minimum+Enrollment+Achieved+in+Hospitalized+Babesiosis+Study%3B+Interim+Data+Readout+Planned+by+October+6%2C+2026/26834756.html Wed, 29 Jul 2026 16:03:00 -0400 A.00641573 A.06822034 A.13379936 A.23195496 A.32073079 O.00168656 O.02027210 O.02114916 O.19918614 O.20026344 O.58280676 SXTP SXTPW